Federal Register / Vol. 62, No. 20 / Thursday, January 30, 1997 / Notices 4535

likely to meet, the standards of the BHC

Act.

Any comments must be submitted in

writing and received by William W.

Wiles, Secretary, Board of Governors of

the Federal Reserve System,

Washington, D.C. 20551, not later than

February 13, 1997.

This application may be inspected at

the offices of the Board of Governors or

the Federal Reserve Bank of Richmond.

Board of Governors of the Federal Reserve

System, January 24, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–2284 Filed 1–29–97; 8:45 am]

BILLING CODE 6210–01–F

Notice of Proposals to Engage in

Permissible Nonbanking Activities or

To Acquire Companies That Are

Engaged in Permissible Nonbanking

Activities

The companies listed in this notice

have given notice under section 4 of the

Bank Holding Company Act (12 U.S.C.

1843) (BHC Act) and Regulation

Y, (12 CFR Part 225) to engage de novo,

or to acquire or control voting securities

or assets of a company that engages

either directly or through a subsidiary or

other company, in a nonbanking activity

that is listed in § 225.25 of Regulation

Y (12 CFR 225.25) or that the Board has

determined by Order to be closely

related to banking and permissible for

bank holding companies. Unless

otherwise noted, these activities will be

conducted throughout the United States.

Each notice is available for inspection

at the Federal Reserve Bank indicated.

Once the notice has been accepted for

processing, it will also be available for

inspection at the offices of the Board of

Governors. Interested persons may

express their views in writing on the

question whether the proposal complies

with the standards of section 4 of the

BHC Act, including whether

consummation of the proposal can

‘‘reasonably be expected to produce

benefits to the public, such as greater

convenience, increased competition, or

gains in efficiency, that outweigh

possible adverse effects, such as undue

concentration of resources, decreased or

unfair competition, conflicts of

interests, or unsound banking practices’’

(12 U.S.C. 1843). Any request for a

hearing on this question must be

accompanied by a statement of the

reasons a written presentation would

not suffice in lieu of a hearing,

identifying specifically any questions of

fact that are in dispute, summarizing the

evidence that would be presented at a

hearing, and indicating how the party

commenting would be aggrieved by

approval of the proposal.

Unless otherwise noted, comments

regarding the applications must be

received at the Reserve Bank indicated

or the offices of the Board of Governors

not later than February 13, 1997.

A. Federal Reserve Bank of Atlanta

(Lois Berthaume, Vice President) 104

Marietta Street, N.W., Atlanta, Georgia

30303-2713:

1. Republic Bancshares, Inc., St.

Petersburg, Florida; to acquire Firstate

Financial, F.A., Orlando, Florida, and

thereby engage in operating a savings

association, pursuant to § 225.25(b)(9)

of the Board’s Regulation Y. The

proposed activity will be conducted

throughout the State of Florida.

Board of Governors of the Federal Reserve

System, January 24, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–2282 Filed 1–29–97; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RETIREMENT THRIFT

INVESTMENT BOARD

Sunshine Act Meeting

TIME AND DATE: 10:00 a.m. (EST),

February 10, 1997.

PLACE: 4th Floor, Conference Room

4506, 1250 H Street, N.W., Washington,

D.C.

STATUS: Open.

MATTERS TO BE CONSIDERED:

1. Approval of the minutes of the January

13, 1997, Board member meeting.

2. Thrift Savings Plan activity report by the

Executive Director.

3. Review of investment policy.

4. Review of KPMG Peat Marwick audit

report: ‘‘Pension and Welfare Benefits

Administration Review of Thrift Savings Plan

C and F Fund Investment Management

Operations at Barclays Global Investors,

N.A.’’

CONTACT PERSON FOR MORE INFORMATION:

Thomas J. Trabucco, Director, Office of

External Affairs, (202) 942–1640.

Dated: January 28, 1997.

Roger W. Mehle,

Executive Director, Federal Retirement Thrift

Investment Board.

[FR Doc. 97–2461 Filed 1–28–97; 2:46 pm]

BILLING CODE 6760–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Advisory Committees; Notice of

Meetings

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: This notice announces

forthcoming meetings of public advisory

committees of the Food and Drug

Administration (FDA). This notice also

summarizes the procedures for the

meetings and methods by which

interested persons may participate in

open public hearings before FDA’s

advisory committees.

FDA has established an Advisory

Committee Information Hotline (the

hotline) using a voice-mail telephone

system. The hotline provides the public

with access to the most current

information on FDA advisory committee

meetings. The advisory committee

hotline, which will disseminate current

information and information updates,

can be accessed by dialing 1–800–741–

8138 or 301–443–0572. Each advisory

committee is assigned a 5-digit number.

This 5-digit number will appear in each

individual notice of meeting. The

hotline will enable the public to obtain

information about a particular advisory

committee by using the committee’s 5-

digit number. Information in the hotline

is preliminary and may change before a

meeting is actually held. The hotline

will be updated when such changes are

made.

MEETINGS: The following advisory

committee meetings are announced:

Arthritis Advisory Committee

Date, time, and place. February 4,

1997, 8:30 a.m., and February 5, 1997,

8 a.m., Gaithersburg Hilton, Ballroom,

620 Perry Pkwy., Gaithersburg, MD.

Type of meeting and contact person.

Open public hearing, February 4, 1997,

8:30 a.m. to 9 a.m., unless public

participation does not last that long;

open committee discussion, 9 a.m. to 5

p.m.; open public hearing, February 5,

1997, 8 a.m. to 8:30 a.m., unless public

participation does not last that long;

open committee discussion, 8:30 a.m. to

5 p.m.; Kathleen R. Reedy or LaNise S.

Giles, Center for Drug Evaluation and

Research (HFD–21), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–443–5455,

FAX: 301–443–0699, or FDA Advisory

Committee Information Hotline, 1–800–

741–8138 (301–443–0572 in the

Washington, DC area), Arthritis